Lam/Tsc Cell Migration to Uterus in an Experimental Model of Lymphangioleiomyomatosis: Regulation by Anti-Epidermal Growth Factor Receptor Antibody and Rapamycin
January 2014
in “
Journal of Cytology & Histology
”
TLDR Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
The study investigated the migration and invasion of human LAM/TSC cells to the uterus using a mouse model, revealing that these cells could migrate without causing morphological lesions but increased angiogenesis. The research involved administering LAM/TSC cells to immunodeficient female nude mice and treating them with rapamycin and anti-EGFR antibody. Both treatments effectively reduced the number of LAM/TSC cells and the proliferation of blood vessels in the uterus, although they did not alter lymphatic vessel expression. This highlighted the strong invasive capability of LAM/TSC cells and the potential of these treatments in managing LAM-related angiogenesis.